LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

98.06 2.7

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

96.98

Max

98.06

Schlüsselkennzahlen
By Trading Economics
Einkommen	-6.3M -53M
Verkäufe	2.8M 51M
EPS	-0.82
Gewinnspanne	-103.131
Angestellte	283
EBITDA	-7.6M -48M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+46.66% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	25. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-616M 6.9B
Vorheriger Eröffnungskurs	95.36
Vorheriger Schlusskurs	98.06

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Feb. 2026, 22:17 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16. Feb. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Feb. 2026, 23:48 UTC

Market Talk

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16. Feb. 2026, 23:23 UTC

Akquisitionen, Fusionen, Übernahmen

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16. Feb. 2026, 23:20 UTC

Akquisitionen, Fusionen, Übernahmen

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16. Feb. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16. Feb. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16. Feb. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16. Feb. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16. Feb. 2026, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16. Feb. 2026, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Bar Very High For Asset Deals

16. Feb. 2026, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16. Feb. 2026, 22:35 UTC

Market Talk

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16. Feb. 2026, 22:02 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16. Feb. 2026, 21:48 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16. Feb. 2026, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16. Feb. 2026, 21:48 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP: China's Economy Resilient; India Continues to Outperform

16. Feb. 2026, 21:47 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16. Feb. 2026, 21:47 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16. Feb. 2026, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16. Feb. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16. Feb. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16. Feb. 2026, 21:46 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP Interim Dividend Represents 60% Payout Ratio

16. Feb. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16. Feb. 2026, 21:45 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16. Feb. 2026, 21:43 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16. Feb. 2026, 21:43 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16. Feb. 2026, 21:42 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16. Feb. 2026, 21:42 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16. Feb. 2026, 21:41 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

46.66% Vorteil

12-Monats-Prognose

Durchschnitt 143.83 USD 46.66%

Hoch 167 USD

Tief 125 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.